Takefumi Komiya1,2, Satomi Yamamoto1, Anuradha Roy3, Peter McDonald3, Raymond P Perez1. 1. Division of Medical Oncology, University of Kansas Medical Center, Fairway, KS, USA. 2. Section of Hematology/Oncology, Tulane University School of Medicine, New Orleans, LA, USA. 3. High Throughput Screening Facility, University of Kansas School of Pharmacy, Lawrence, KS, USA.
Abstract
BACKGROUND: Our previous study suggested NR4A2, a subfamily member of orphan nuclear receptors, is essential for survival of human cancer cells such as mucoepidermoid carcinoma (MEC). METHODS: We conducted high throughput drug screening for NR4A2 inhibitors as a novel therapeutic modality. Positive screening was performed using a luciferase reporter vector containing NR4A2 binding sequence, and a CRE-reporter control vector was used to eliminate false positives. In vitro assays for positive hits were conducted. RESULTS: A total of 23 Food and Drug Administration (FDA) and 43 Life Science Library compounds were identified, including several epidermal growth factor inhibitors and Src inhibitors. Subsequent in vitro assays confirmed that identified compounds were preferentially active in NR4A2+ cancer cells. Several candidate compounds appeared to suppress NR4A2 via inhibition of p-ERK, whereas a novel compound KU0171309 may act as a more direct inhibitor. CONCLUSIONS: Further research should focus on homologue selectivity, in vivo activity, and definitively deciphering the mechanism of action of KU0171309.
BACKGROUND: Our previous study suggested NR4A2, a subfamily member of orphan nuclear receptors, is essential for survival of human cancer cells such as mucoepidermoid carcinoma (MEC). METHODS: We conducted high throughput drug screening for NR4A2 inhibitors as a novel therapeutic modality. Positive screening was performed using a luciferase reporter vector containing NR4A2 binding sequence, and a CRE-reporter control vector was used to eliminate false positives. In vitro assays for positive hits were conducted. RESULTS: A total of 23 Food and Drug Administration (FDA) and 43 Life Science Library compounds were identified, including several epidermal growth factor inhibitors and Src inhibitors. Subsequent in vitro assays confirmed that identified compounds were preferentially active in NR4A2+ cancer cells. Several candidate compounds appeared to suppress NR4A2 via inhibition of p-ERK, whereas a novel compound KU0171309 may act as a more direct inhibitor. CONCLUSIONS: Further research should focus on homologue selectivity, in vivo activity, and definitively deciphering the mechanism of action of KU0171309.
Entities:
Keywords:
NR4A2; cAMP responsive element binding (CREB)-regulated transcription coactivator 1-Mastermind-like protein 2 (CRTC1-MAML2); drug screening; mucoepidermoid carcinoma (MEC); non-small cell lung cancer (NSCLC)
Authors: Giovanni Tonon; Sanjay Modi; Lizi Wu; Akihito Kubo; Amy B Coxon; Takefumi Komiya; Kevin O'Neil; Kristen Stover; Adel El-Naggar; James D Griffin; Ilan R Kirsch; Frederic J Kaye Journal: Nat Genet Date: 2003-01-21 Impact factor: 38.330
Authors: J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson Journal: Science Date: 2004-04-29 Impact factor: 47.728
Authors: Mehrdad Zarei; Rupesh Shrestha; Sneha Johnson; Zuhua Yu; Keshav Karki; Ali Vaziri-Gohar; Jessica Epps; Heng Du; Larry Suva; Mahsa Zarei; Stephen Safe Journal: Cancer Res Commun Date: 2021-11